Lv31
300 积分 2024-03-01 加入
Trends in use of poly (ADP-ribose) polymerase inhibitor (PARPi) in ovarian cancer
3小时前
求助中
Chemoresistance in ovarian cancer (I)
3小时前
求助中
PARP inhibitor maintenance treatment for newly diagnosed ovarian cancer patients: a real-world study from China
2个月前
已完结
Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2 and a scar-based HRD signature in real-world practice
2个月前
已完结
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial
4个月前
已完结
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort
4个月前
已完结
[Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients]
4个月前
已完结
Mechanism of Action of PARP Inhibitors
5个月前
已完结
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
5个月前
已完结
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer
5个月前
已完结
皖公网安备34019202002308
